Efemoral Medical, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Efemoral Medical, Inc.
News We're Watching: Accenture Expects 'More Human' Tech, Cardiac Genetic Tests In Walmart; And More
Medtech Insight's News We're Watching highlights a few noteworthy industry developments you might have missed: Accenture's new Vision Report addresses the future of "more human" tech in health care; Efemoral secures FDA's breakthrough status for its bioresorbable peripheral stent; Impulse Dynamics secures $135m to support its cardiac contractility modulation; PrecisionLife and Metrodora announced a partnership to address chronic diseases including long COVID; Cardio Diagnostics launches its cardiac epigenetic/genetic tests in a Walmart near Chicago.
Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.
IQuity Lands NIH Grant To Help Identify Alzheimer's Early
The $320k grant will support research that builds on IQuity’s autoimmune diagnostic expertise and new data analytics platform. The company believes the emerging therapies for Alzheimer's will be most effective if they are used to treat the disease early in its progression.
iQuity Shifts From Test-Maker To Data Miner And Analyzer
Nashville-based genomics company iQuity is building a data mining and analytics platform that will predict and monitor chronic diseases from public and private datasets from large populations.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice